Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02294435
Recruitment Status : Recruiting
First Posted : November 19, 2014
Last Update Posted : April 4, 2019
Sponsor:
Information provided by (Responsible Party):
Patrick Kelly, Sanford Health

Brief Summary:
The primary objective of the Visceral Manifold and Unitary Device Study is to assess the use of the thoracic bifurcation and the visceral manifold or the unitary device to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device. Additionally, the study will assess technical success and treatment success at each follow-up interval.

Condition or disease Intervention/treatment Phase
Thoracoabdominal Aneurysms Device: Visceral Manifold and Thoracic Bifurcation Device: Unitary Manifold Not Applicable

Detailed Description:
The primary objective of the clinical investigation Visceral Manifold and Unitary Device Study is to assess the use of the thoracic bifurcation and the visceral manifold or the unitary stent graft system to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety (i.e. freedom from major adverse events (MAE) at 30 days) and preliminary effectiveness (i.e., treatment success and technical success) of the device (i.e., the proportion of treatment group subjects that achieve and maintain treatment success at one year). Additionally, the study will assess technical success and treatment success at each follow-up interval.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms
Study Start Date : February 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Primary Study Arm
The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
Device: Visceral Manifold and Thoracic Bifurcation
Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system

Device: Unitary Manifold
Unitary Manifold Endovascular stent graft system

Experimental: Expanded Selection Arm
The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
Device: Visceral Manifold and Thoracic Bifurcation
Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system

Device: Unitary Manifold
Unitary Manifold Endovascular stent graft system




Primary Outcome Measures :
  1. Freedom from major adverse events (MAEs) at 30 days [ Time Frame: 30 days ]
    Major adverse events include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, and stroke.


Secondary Outcome Measures :
  1. Treatment success and technical success at 1 year [ Time Frame: 1 year ]

    Treatment success is defined as a composite of technical success and freedom from the following:

    • Aneurysm enlargement
    • Aneurysm rupture
    • Aneurysm-related mortality
    • Conversion to open repair
    • Secondary intervention for migration, Type I and III endoleaks, device integrity failure , and patency-related events

  2. Treatment success at various timepoints [ Time Frame: 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years ]

    Treatment success and the individual components of treatment success including freedom from the following:

    • Aneurysm enlargement
    • Aneurysm-related mortality
    • Aneurysm rupture
    • Conversion to open repair
    • Secondary intervention for migration, type I and III endoleaks, device integrity failure, and patency-related events.
    • Renal failure
    • All-cause mortality
    • Endoleaks
    • Device integrity failure
    • Patency-related events
    • Other device-related events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • An aneurysm with a maximum diameter of ≥ 5.5 cm or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements
  • Aneurysm with a history of growth ≥ 0.5 cm in 6 months
  • Saccular aneurysm deemed at significant risk for rupture
  • Symptomatic aneurysm greater than or equal to 4.5 cm
  • Axillary or brachial and iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit
  • Proximal landing zone for the thoracic bifurcation stent graft:

    •≥ 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA)

    • Diameter in the range of 26-42 mm
    • Adequate distance from the celiac artery, in order to accommodate cannulation from the antegrade access point when considering the total deployed length of the thoracic bifurcation and visceral manifold
  • Proximal landing zone for the unitary manifold stent graft:

    • Nonaneurysmal aortic segment including previously placed graft material (neck) with a minimum seal zone length of 3 cm
    • Diameter in the range of 19-32 mm
  • Iliac artery or aortic distal fixation site greater than or equal to 15 mm in length and diameter in the range of 8 - 25 mm
  • Age: ≥ 18 years old
  • Life expectancy: > 1 year

Exclusion Criteria:

General exclusion

  • Patient is a good candidate for and elects for open surgical repair
  • Can be treated in accordance with the instructions for use with a legally marketed
  • Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
  • Unwilling to comply with the follow-up schedule
  • Inability or refusal to give informed consent
  • Urgent or emergent presentation
  • Patient is pregnant or breastfeeding
  • Patient has a contained rupture
  • Patient has a ruptured aneurysm
  • Patient has a dissection in the portion of the aorta intended to be treated
  • Obstructive stenting of any or all of the visceral vessels
  • Poor performance status including two major system failures (cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular)

Medical exclusion criteria

  • Known sensitivities or allergies to the materials of construction of the devices, including nitinol (Nickel:Titanium), polyester, platinum-iridium, polytetrafluoroethylene (PTFE)
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
  • Uncorrectable coagulopathy
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
  • Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned < 30 days of the endovascular repair
  • Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina)
  • Systemic or local infection that may increase the risk of endovascular graft infection
  • Baseline creatinine greater than 2.0 mg/dL
  • History of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)
  • Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in a landing zone that expands beyond any limits of the previously placed graft material

Anatomical exclusion criteria

  • Minimum branch vessel diameter less than 5 mm
  • Thrombus or excessive calcification within the neck of the aneurysm
  • Anatomy that would not allow maintenance of at least one patent hypogastric artery
  • Anatomy that would not allow primary or assisted patency of the left subclavian artery

Expanded Selection Arm Inclusion Criteria

Patient that meets the criteria for inclusion in the primary study arm but has one or more of the following criteria which would exclude them from the primary study arm:

  • Minimum branch vessel diameter less than 5 mm
  • Urgent or emergent presentation
  • Patient has a contained rupture
  • Patient has a ruptured aneurysm
  • Patient has a type B dissection (subacute or chronic) in the portion of the aorta intended to be treated
  • Poor performance status including two major system failures (cardiovascular, pulmonary, renal, hepatobiliary, and neuromuscular)
  • Baseline creatinine greater than or equal to 2.0 mg/dL
  • Anatomy that would not allow for maintenance of at least one hypogastric artery
  • Anatomy that would not allow for primary or assisted patency of the left subclavian artery
  • Prior aneurysm repair that would involve relining of the previously placed graft material requiring placement of the investigational system in the a landing zone that expands beyond any limits of the previously placed graft material
  • Obstructive stenting of any or all of the visceral vessels

OR

Patient that meets criteria for inclusion in the primary study arm and:

  • Would not be eligible for the primary study arm per a documented reason other than those outlined above, and
  • Per the opinion of the Principal Investigator, with concurrence of the IRB, alternative therapies are unsatisfactory and the probable risk of using the investigational device is no greater than the probable risk from the disease or condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02294435


Contacts
Layout table for location contacts
Contact: Patrick Kelly, MD 605-312-7300 patrick.kelly@sanfordhealth.org
Contact: Katie Pohlson 605-312-7714 kathryn.pohlson@sanfordhealth.org

Locations
Layout table for location information
United States, South Dakota
Sanford Health Recruiting
Sioux Falls, South Dakota, United States, 57117
Contact: Nicole Wendling, RN    605-312-7300      
Principal Investigator: Patrick W Kelly, MD         
Sponsors and Collaborators
Sanford Health
Investigators
Layout table for investigator information
Principal Investigator: Patrick Kelly, MD Sanford Health

Publications:
Layout table for additonal information
Responsible Party: Patrick Kelly, Principal Investigator, Sanford Health
ClinicalTrials.gov Identifier: NCT02294435     History of Changes
Other Study ID Numbers: SH VMS
First Posted: November 19, 2014    Key Record Dates
Last Update Posted: April 4, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Keywords provided by Patrick Kelly, Sanford Health:
Thoracoabdominal Aneurysms
Endovascular
Ps-ide
Early Feasibility
Aneurysm
Aortic Aneurysm, Thoracic
Aortic Aneurysm
Aortic Diseases
Cardiovascular Diseases
Vascular Diseases
Pararenal aneurysm
Juxtarenal aneurysm
Aortic dissection
Short neck infrarenal aneurysm
Type 4 thoracoabdominal
TAAA

Additional relevant MeSH terms:
Layout table for MeSH terms
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Thoracic
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases